GO-203-2C
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for GO-203-2C, covering 2014-09-19 to 2026-04-03. Get the full timeline:
Most recent: Clinical Trial Update: A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]